Anurag Bagaria

Anarug holds a degree in Chemical Engineering from Cornell University and an MBA from the Kellogg School of Management. Anurag Bagaria is the Chairman & CEO of Kemwell Biopharma, India's largest biopharmaceutical CDMO providing customized process development, product development and manufacturing solutions to global biopharmaceutical companies. Anurag joined Kemwell in 2004 as a second-generation entrepreneur and became Chairman in 2010. He expanded Kemwell's facilities in India, Sweden and the U.S., providing CDMO services for small and large molecule drugs for global markets. In 2017, he leg the sale of Kemwell's small-molecule services business to Recipharm AB.

Anurag also services on the Board of Stempeutics, a company developing stem-cell based therapeutics, and is a board observer on Apexigen Inc, a clinical-developer of antibody therapeutics against cancer, among other drug-development startups that he is actively involved with.